Last reviewed · How we verify

NCT04633798

Evaluation of the Efficacy of Intense Pulse Light Combined With Lipiflow in the Treatment of Meibomian Gland Dysfunction

Status unknown NA Last updated 18 November 2020
What this trial tests

NA trial testing IPL/Lipiflow in Meibomian Gland Dysfunction in 100 participants. Status unknown.

Timeline
1 December 2020
Primary endpoint
21 December 2020
21 December 2020

Quick facts

Lead sponsorAier School of Ophthalmology, Central South University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment100
Start date1 December 2020
Primary completion21 December 2020
Estimated completion21 December 2020

Drugs / interventions tested

Conditions studied

Sponsor

Aier School of Ophthalmology, Central South University

Who can join

Adults 18 to 80, any sex, with Meibomian Gland Dysfunction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To compare the effect of IPL combined with lipiflow and IPL combined with meibomian gland massage in treating meibomian gland dysfunction of different degrees ,focusing on effective rate, lasting time and changes of meibomian gland function and morphology.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. LipiFlow for the treatment of dry eye disease.
    Pucker AD, Yim TW, Rueff E, Ngo W, et al · · 2024 · cited 11× · PMID 38314898 · DOI 10.1002/14651858.cd015448.pub2

Verify or expand the search:

Other recruiting trials for Meibomian Gland Dysfunction

Currently open trials in the same condition.

Other Aier School of Ophthalmology, Central South University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04633798.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing